Ultragenyx Reports Preliminary 2021 Revenue and 2022 Revenue Guidance for Crysvita® in Ultragenyx Territories* And Dojolvi® Globally; Provides Pipeline Updates and 2022 Milestones
January 10, 2022 08:00 ET
|
Ultragenyx Pharmaceutical Inc.
Preliminary 2021 Crysvita revenue in Ultragenyx territories of $191 million to $193 million and Dojolvi revenue of $38 million to $40 million 2022 Crysvita revenue in Ultragenyx territories expected...